Novel Phloroglucinol Derivatives as Neuraminidase Inhibitors Identified From Humulus lupulus L. Extract by At-Line
Zhixu Chen1,2, Biao Sun1,3,4, Hanlin Zeng1
1Institute of Pharmaceutical Analysis, College of Pharmacy; Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research; International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, Jinan University, Guangzhou, China.
None:
Neuraminidase inhibitors (NAIs) are a crucial therapy for combatting the influenza virus. This study employed an at-line nanofractionation technique to precisely localized potential NAIs in the extract of Humulus lupulus L. Twelve potential compounds, mainly phloroglucinol derivatives, were screened and identified. Seven of these compounds were subsequently isolated, purified, and structurally elucidated by NMR. Among them, Compound 5 showed remarkable inhibitory activity against both neuraminidase (NA, IC50 = 0.8 µM) and the H3N2 influenza virus (EC50 = 3.8 µM), confirming its potential as a lead compound for anti-influenza development. Compounds 4 and 8, identified as hitherto uncharacterized phloroglucinol derivatives, also demonstrated significant inhibition against NA and the H3N2 influenza virus. Molecular docking revealed that Compounds 4 and 5 exhibited superior binding affinities compared to oseltamivir, with 4 forming critical hydrogen bonds with acidic residues (Glu119, Glu227, and Asp151) in the "150-cavity," which significantly enhances its inhibitory potency against NAs.
Related Concept Videos
Inhibitors Of Virion Release
Antiviral Nucleoside Inhibitors


